Full-Body MRI Scans: The $2,500 Celebrity Health Trend Turning Healthy People Into Patients

Medicine is considerably less simple.

For average-risk people without symptoms, major medical organisations do not recommend routine full-body MRI screening. The American College of Radiology has said there is no evidence that the practice is cost-effective or extends life. Major reviews in JAMA and JAMA Internal Medicine have reached similar conclusions.

The conflict is no longer simply between one medical test and one medical guideline. It is becoming a contest between two models of healthcare: one in which doctors and evidence determine who should be screened, and another in which consumers can purchase increasingly sophisticated diagnostics directly.

The problem with finding more

A full-body MRI can reveal something that conventional, symptom-driven medicine might never have looked for. That is precisely what makes the technology both attractive and difficult to assess.

The available evidence points to a striking imbalance. Meta-analyses covering thousands of asymptomatic people put the rate of confirmed cancer detection at roughly 1.1% to 1.6%. In one synthesis of 10 studies involving 9,024 people, the rate was 1.57%.

Incidental findings are dramatically more common. Between 37% and 50% of asymptomatic people undergoing full-body MRI have at least one abnormality detected. Around 32% of scans generate findings considered critical or ambiguous enough to require further clinical assessment. The false-positive rate is about 16%.

And most of those abnormalities do not turn out to be dangerous. Between 80% and 90% of incidental findings are ultimately judged benign, including cysts, vascular abnormalities and structural scars.

The scan, therefore, does not simply answer the question, “Are you ill?”

It can create a much larger chain of questions.

An apparently healthy consumer may leave a screening centre with an abnormal result that requires another scan, contrast imaging, specialist assessment or biopsy. In some cases, patients undergo surgery. Estimates in the evidence reviewed put the proportion of asymptomatic people funnelled into secondary medical procedures as high as 29% to 30%.

This is where the economics of retail screening become harder to see.

The consumer pays $2,500 for the initial scan. The healthcare system must then absorb the consequences of what that scan finds.

A false positive is not the same as overdiagnosis

The distinction matters because the harms do not end when a suspicious result is shown to be benign.

A false positive occurs when a test indicates a possible abnormality that further investigation ultimately shows is not the disease suspected. It can mean more imaging, a biopsy, anxiety, and expense before the patient is told that nothing serious was found.

Overdiagnosis is more complicated.

A scan may correctly identify a genuine tumour or other abnormality that would never have caused symptoms or shortened the person's life. The diagnosis is therefore not necessarily wrong. The problem is that knowing about it can trigger treatment that provides no meaningful benefit.

That can mean surgery, radiation, chemotherapy or other interventions for a condition that would otherwise have remained harmless.

This is one reason the success story of an individual patient cannot establish whether a screening programme works.

Philipps’ tumour was real, and its discovery may have been consequential for her. But an individual case cannot show whether scanning thousands or millions of healthy people will reduce mortality. That requires outcome evidence comparing screened and unscreened populations.

There are currently no randomised controlled trials demonstrating that routine full-body MRI reduces overall or cancer-specific mortality among healthy, average-risk adults.

A market built around uncertainty

The commercial model has flourished precisely where the evidence remains unsettled.

Prenuvo operates through a cash-pay model, selling a sophisticated diagnostic experience directly to consumers rather than relying on conventional insurance pathways. The company also works with influencers, including offering free scans and promotional discount codes. In Philipps’ case, Prenuvo’s president and chief medical officer, Dr Daniel Durand, said she paid for the examination herself.

That distinction matters less than the marketing effect.

A celebrity describing a potentially life-saving discovery compresses an extremely complicated statistical question into a powerful personal narrative. The consumer does not experience the probability distribution behind thousands of scans. They see one person who found something dangerous because she looked.

Social media is particularly well suited to this kind of message. A 2025 analysis of nearly 1,000 TikTok and Instagram posts about full-body scans found that only 15% explicitly addressed clinical risks, false positives, or the downstream consequences of abnormal findings.

The missing information is the crucial information.

A scan can be presented as proactive, empowering, and technologically sophisticated, while the less marketable possibility - that it may produce years of surveillance for a harmless abnormality - receives little attention.

That creates an unusually asymmetric transaction. The company understands the uncertainty inherent in screening. The consumer is being sold the feeling of certainty.

Medicine's gatekeepers are losing ground

Traditional screening has always involved a degree of gatekeeping. A physician assesses symptoms, age, family history, and risk before recommending a particular test. Guidelines constrain what is offered routinely because every diagnostic intervention has potential costs as well as benefits.

Direct-to-consumer medicine changes that relationship.

A healthy person no longer needs to persuade a doctor that a whole-body scan is medically warranted. If they can pay, the test can become a consumer purchase. The decision is framed less as a clinical judgement than as an investment in personal wellbeing.

That is an important shift in healthcare delivery.

It also changes who carries the risk. The screening company receives revenue from the initial procedure. The patient bears the immediate financial cost. If the scan produces an incidental finding, the patient may face further bills and psychological distress. Meanwhile, doctors, radiologists, hospitals, and diagnostic services may have to investigate abnormalities generated outside conventional screening pathways.

The technology itself is not necessarily the problem. MRI remains a valuable diagnostic tool, and full-body MRI has legitimate uses in specific high-risk populations, including people with verified genetic cancer predisposition syndromes such as Li-Fraumeni syndrome or those with strong family medical histories.

The unresolved question is where that medical value ends, and retail medicine begins.

The evidence has not caught up with the business

Dr Durand has acknowledged that full-body screening remains an evolving area of medicine and requires longer-term studies, while arguing that the cost of missed or delayed diagnoses justifies the approach.

That is a legitimate medical question. It is not, however, the same as evidence that routine screening saves lives.

Researchers including H. Gilbert Welch of Mass General Brigham and Rebecca Smith-Bindman of UCSF have warned about overdiagnosis, anxiety, and the financial incentives surrounding such testing. Their concern is not that doctors should stop looking for cancer. It is that looking indiscriminately at healthy bodies can create a cascade of interventions whose harms are easier to generate than their benefits are to prove.

That distinction is increasingly important as diagnostic technology becomes easier to buy.

The central promise of consumer health is autonomy: give people access to more information and let them make better decisions. But medical information is not automatically beneficial simply because it is available. An abnormality without a clear clinical significance can be less like knowledge than an unresolved liability.

Celebrity stories make that uncertainty particularly difficult to communicate. They provide an emotionally compelling answer to a question that medical research has not yet settled.